移植片対宿主病(GVHD)の疫学予測

DelveInsightが発行した調査報告書(DELV803010)
◆英語タイトル:Graft versus host disease (GVHD)- Epidemiology Forecast
◆商品コード:DELV803010
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年3月
◆ページ数:122
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥367,250見積依頼/購入/質問フォーム
Site Price(同一事業所内共有可)USD6,500 ⇒換算¥734,500見積依頼/購入/質問フォーム
Enterprise Price(同一法人内共有可)USD9,750 ⇒換算¥1,101,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s ‘Graft versus Host Disease (GvHD) – Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Graft versus Host Disease (GvHD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Graft versus Host Disease (GvHD) Epidemiology
The Graft versus Host Disease (GvHD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Graft versus Host Disease (GvHD) are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
According to DelveInsight, the diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs) in 7 major markets was 53,601 (which includes 21,408 Incident cases of first allogeneic HSCT) in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM United States account for highest diagnosed incident cases of aGvHD and cGvHD in diagnosed incident cases of First Allogeneic HSCTs followed by Germany.

Graft versus Host Disease (GvHD) Epidemiology Segmentation
The disease epidemiology covered in the report is segmented by sub-type [Acute GvHD (aGvHD) and Chronic GvHD (cGvHD)] and grades of aGvHD [I, II, III and IV]. The epidemiology section of report further includes diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs). It also includes diagnosed incident cases of aGvHD and cGvHD, 4-Year diagnosed prevalent cases of aGvHD and 5-Year diagnosed prevalent cases of cGvHD in diagnosed incident cases of First Allogeneic HSCTs.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Report Scope
• The report covers detailed overview of Graft versus Host Disease (GvHD) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of Graft versus Host Disease (GvHD)
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by sub-type [Acute GvHD (aGvHD) and Chronic GvHD (cGvHD)] and grades of aGvHD [I, II, III and IV]

Key strengths
• 10 Year Forecast of Graft versus Host Disease (GvHD) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Graft versus Host Disease (GvHD)
• Incident Cases according to segmentation: diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs), diagnosed incident cases of aGvHD and cGvHD, 4-Year diagnosed prevalent cases of aGvHD and 5-Year diagnosed prevalent cases of cGvHD in diagnosed incident cases of First Allogeneic HSCTs

Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

【レポートの目次】

1. Report Introduction 1
2. GvHD Epidemiology Overview at a Glance 2
3. 2
4. Market Share Distribution of GvHD in 2027 2
5. Disease Background and Overview: Graft versus Host Disease (GvHD) 19
5.1. Introduction 19
5.2. Disease Types 19
5.3. Acute GvHD 19
5.4. Chronic GvHD 19
5.5. Grades of GvHD 20
5.6. Pathophysiology 22
5.7. Risk Factors for GVHD 23
5.8. Diagnosis 24
6. Epidemiology and Patient Population 26
6.1. Key Findings 26
6.1.1. Population and Forecast Parameters 27
6.1.2. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations in 7MM 28
6.1.3. Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM– By Region 29
6.1.4. Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM– By Region 30
6.1.5. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in 7MM-2016 31
6.1.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in 7MM-2027 31
6.1.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in 7MM-2016 32
6.1.8. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in 7MM-2027 32
6.1.9. Epidemiology of Graft Versus Host Disease 33
6.2. United States 33
6.2.1. Assumptions and Rationale 33
6.2.2. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States 37
6.2.3. Diagnosed Incident Cases of Allogeneic HSCT in United States 39
6.2.4. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in US 40
6.2.5. Incident cases of aGvHD by Grades in US 42
6.2.6. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in US 43
6.2.7. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United States 45
6.2.8. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United States 46
6.3. EU5 47
6.4. Assumptions and Rationale 47
6.5. Germany 48
6.5.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany 48
6.5.2. Diagnosed Incident Cases of Allogeneic HSCT in Germany 49
6.5.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Germany 50
6.5.4. Incident cases of aGvHD by Grades in Germany 52
6.5.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Germany 53
6.5.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Germany 55
6.5.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Germany 56
6.6. France 57
6.6.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France 57
6.6.2. Diagnosed Incident Cases of Allogeneic HSCT in France 58
6.6.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in France 59
6.6.4. Incident cases of aGvHD by Grades in France 60
6.6.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in France 61
6.6.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in France 62
6.6.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in France 63
6.7. Italy 64
6.7.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy 64
6.7.2. Diagnosed Incident Cases of Allogeneic HSCT in Italy 65
6.7.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Italy 66
6.7.4. Incident cases of aGvHD by Grades in Italy 68
6.7.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Italy 69
6.7.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Italy 70
6.7.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Italy 71
6.8. Spain 72
6.8.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain 72
6.8.2. Diagnosed Incident Cases of Allogeneic HSCT in Spain 73
6.8.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Spain 74
6.8.4. Incident cases of aGvHD by Grades in Spain 75
6.8.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Spain 76
6.8.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Spain 77
6.8.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Spain 78
6.9. United Kingdom 79
6.9.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom 79
6.9.2. Diagnosed Incident Cases of Allogeneic HSCT in United Kingdom 80
6.9.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in United Kingdom 81
6.9.4. Incident cases of aGvHD by Grades in United Kingdom 82
6.9.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in United Kingdom 83
6.9.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United Kingdom 84
6.9.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United Kingdom 85
6.10. Japan 86
6.10.1. Assumptions and Rationale 86
6.10.2. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan 87
6.10.3. Diagnosed Incident Cases of Allogeneic HSCT in Japan 88
6.10.4. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Japan 89
6.10.5. Incident cases of aGvHD by grades in Japan 91
6.10.6. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Japan 92
6.10.7. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Japan 93
6.10.8. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Japan 94
7. Unmet Needs 109
8. Appendix 119
9. Report Methodology 119
10. Sources Used 119
11. Consulting Services 121
12. Disclaimer 122
13. About DelveInsight 122

Table 1: Glucksberg Clinical stage of Acute GvHD 20
Table 2: Glucksberg grade of Acute GvHD 20
Table 3: Global scoring of cGvHD 21
Table 4:Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations in 7 MM (2016-2027) 28
Table 5: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region(2016-2027) 29
Table 6: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region (2016-2027) 30
Table 7: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2016-2027) 38
Table 8: Diagnosed Incident Cases of Allogeneic HSCT in United States in United States (2016-2027) 39
Table 9: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027) 41
Table 10: Incident cases of aGvHD by grades in United States (2016-2027) 42
Table 11: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027) 44
Table 12: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United States (2016-2027) 45
Table 13: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United States (2016-2027) 46
Table 14: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2016-2027) 48
Table 15: Diagnosed Incident Cases of Allogeneic HSCT in Germany (2016-2027) 49
Table 16: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027) 51
Table 17: Incident cases of aGvHD by grades in Germany (2016-2027) 52
Table 18: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027) 54
Table 19: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Germany (2016-2027) 55
Table 20: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Germany (2016-2027) 56
Table 21: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2016-2027) 57
Table 22: Diagnosed Incident Cases of Allogeneic HSCT in France (2016-2027) 58
Table 23: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027) 59
Table 24: Incident cases of aGvHD by grades in France (2016-2027) 60
Table 25: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027) 61
Table 26: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in France (2016-2027) 62
Table 27: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in France (2016-2027) 63
Table 28: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2016-2027) 64
Table 29: Diagnosed Incident Cases of Allogeneic HSCT in Italy (2016-2027) 65
Table 30: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027) 67
Table 31: Incident cases of aGvHD by grades in Italy (2016-2027) 68
Table 32: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027) 69
Table 33: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Italy (2016-2027) 70
Table 34: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Italy (2016-2027) 71
Table 35: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2016-2027) 72
Table 36: Diagnosed Incident Cases of Allogeneic HSCT in Spain (2016-2027) 73
Table 37: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027) 74
Table 38: Incident cases of aGvHD by grades in Spain (2016-2027) 75
Table 39: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027) 76
Table 40: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Spain (2016-2027) 77
Table 41: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Spain (2016-2027) 78
Table 42: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2016-2027) 79
Table 43: Diagnosed Incident Cases of Allogeneic HSCT in United Kingdom (2016-2027) 80
Table 44: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027) 81
Table 45: Incident cases of aGvHD by grades in United Kingdom (2016-2027) 82
Table 46: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027) 83
Table 47: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027) 84
Table 48: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027) 85
Table 49: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2016-2027) 87
Table 50: Diagnosed Incident Cases of Allogeneic HSCT in Japan (2016-2027) 88
Table 51: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027) 90
Table 52: Incident cases of aGvHD by grades in Japan (2016-2027) 91
Table 53: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027) 92
Table 54: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Japan (2016-2027) 93
Table 55: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Japan (2016-2027) 94


Figure 1: Pathophysiology of GvHD 22
Figure 2: Risk Factors for GvHD 23
Figure 3: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations in 7 MM (2016-2027) 28
Figure 4: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region(2016-2027) 29
Figure 5: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region(2016-2027) 30
Figure 6: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2016-2027) 38
Figure 7: Diagnosed Incident Cases of Allogeneic HSCT in United States (2016-2027) 39
Figure 8: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027) 41
Figure 9: Incident cases of aGvHD by grades in United States (2016-2027) 42
Figure 10: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027) 44
Figure 11: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United States (2016-2027) 45
Figure 12: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United States (2016-2027) 46
Figure 13: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2016-2027) 48
Figure 14: Diagnosed Incident Cases of Allogeneic HSCT in Germany (2016-2027) 49
Figure 15: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027) 51
Figure 16: Incident cases of aGvHD by grades in Germany (2016-2027) 52
Figure 17: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027) 54
Figure 18: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Germany (2016-2027) 55
Figure 19: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Germany (2016-2027) 56
Figure 20: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2016-2027) 57
Figure 21: Diagnosed Incident Cases of Allogeneic HSCT in France (2016-2027) 58
Figure 22: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027) 59
Figure 23: Incident cases of aGvHD by grades in France (2016-2027) 60
Figure 24: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027) 61
Figure 25: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in France (2016-2027) 62
Figure 26: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in France (2016-2027) 63
Figure 27: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2016-2027) 64
Figure 28: Diagnosed Incident Cases of Allogeneic HSCT in Italy (2016-2027) 65
Figure 29: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027) 67
Figure 30: Incident cases of aGvHD by grades in Italy (2016-2027) 68
Figure 31: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027) 69
Figure 32: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Italy (2016-2027) 70
Figure 33: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Italy (2016-2027) 71
Figure 34: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2016-2027) 72
Figure 35: Diagnosed Incident Cases of Allogeneic HSCT in Spain (2016-2027) 73
Figure 36: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027) 74
Figure 37: Incident cases of aGvHD by grades in Spain (2016-2027) 75
Figure 38: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027) 76
Figure 39: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Spain (2016-2027) 77
Figure 40: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Spain (2016-2027) 78
Figure 41: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2016-2027) 79
Figure 42: Diagnosed Incident Cases of Allogeneic HSCT in United Kingdom (2016-2027) 80
Figure 43: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027) 81
Figure 44: Incident cases of aGvHD by grades in United Kingdom (2016-2027) 82
Figure 45: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027) 83
Figure 46: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027) 84
Figure 47: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027) 85
Figure 48: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2016-2027) 87
Figure 49: Diagnosed Incident Cases of Allogeneic HSCT in Japan (2016-2027) 88
Figure 50: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027) 90
Figure 51: Incident cases of aGvHD by grades in Japan (2016-2027) 91
Figure 52: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027) 92
Figure 53: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Japan (2016-2027) 93
Figure 54: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Japan (2016-2027) 94


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 移植片対宿主病(GVHD)の疫学予測(Graft versus host disease (GVHD)- Epidemiology Forecast)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆